A detailed history of Nuveen Asset Management, LLC transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 304,611 shares of PSTX stock, worth $2.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
304,611
Previous 402,881 24.39%
Holding current value
$2.88 Million
Previous $1.18 Million 25.94%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.7 - $4.04 $265,329 - $397,010
-98,270 Reduced 24.39%
304,611 $871,000
Q2 2024

Aug 09, 2024

BUY
$2.0 - $3.46 $261,388 - $452,201
130,694 Added 48.02%
402,881 $1.18 Million
Q1 2024

May 13, 2024

SELL
$2.76 - $4.13 $28,825 - $43,133
-10,444 Reduced 3.7%
272,187 $868,000
Q4 2023

Feb 14, 2024

SELL
$1.83 - $3.51 $151,084 - $289,785
-82,560 Reduced 22.61%
282,631 $949,000
Q2 2023

Aug 14, 2023

BUY
$1.66 - $3.4 $606,217 - $1.24 Million
365,191 New
365,191 $642,000
Q2 2022

Aug 15, 2022

SELL
$1.87 - $5.0 $185,058 - $494,810
-98,962 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$3.22 - $7.04 $4,404 - $9,630
1,368 Added 1.4%
98,962 $463,000
Q4 2021

Feb 14, 2022

SELL
$6.23 - $7.6 $62,860 - $76,684
-10,090 Reduced 9.37%
97,594 $643,000
Q3 2021

Nov 12, 2021

BUY
$7.09 - $10.71 $58,761 - $88,764
8,288 Added 8.34%
107,684 $862,000
Q2 2021

Aug 16, 2021

BUY
$7.96 - $10.07 $3,908 - $4,944
491 Added 0.5%
99,396 $996,000
Q1 2021

May 17, 2021

BUY
$8.51 - $11.91 $554,877 - $776,567
65,203 Added 193.47%
98,905 $945,000
Q4 2020

Feb 16, 2021

BUY
$8.29 - $11.7 $93,461 - $131,905
11,274 Added 50.27%
33,702 $370,000
Q3 2020

Nov 16, 2020

BUY
$8.09 - $16.25 $181,442 - $364,455
22,428 New
22,428 $199,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $810M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.